AbbVie Inc. (NYSE:ABBV) [Trend Analysis] said it will buy Pharmacyclics Inc, the maker of blockbuster cancer drug Imbruvica, for about $21 billion to boost its oncology drugs pipeline. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock’s closing price on Wednesday on the Nasdaq. AbbVie Inc. (NYSE:ABBV) after opening at $59.32 hit its intraday high price of $60.42 moreover then finished at $60.27 as shares moving up 1.09%. As took noticed on the firm performance, its weekly performance was -0.58%, monthly performance was -0.71%. The stock price of ABBV is moving up from its 20 days moving average with 2.24% and isolated negatively from 50 days moving average with -3.08%.
www.emarketsdaily.com/...seabbv-catalent-inc-nysectlt/1830984/
www.emarketsdaily.com/...seabbv-catalent-inc-nysectlt/1830984/